Merck SharpDohme LLC
PD-1 antibody(Merck Sharp & Dohme LLC)은 PD-1 표적 항체로, Locally Recurrent Rectal Cancer 영역에서 개발·상용화 중입니다. 작용기전: target for cancer immunotherapy due to its negatively regulatory effect on the STING pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 56.1% (ClinicalTrials.gov NCT02289209). PK: t½ 35.14 h. 차별점: novel AXL inhibitor 4j , which was discovered through structure-based drug design, SAR-driven optimization, and pharmacokinet.
PD-1
Locally Recurrent Rectal Cancer
Recruiting
to
cleavable peptide linker
humanized Fc domains and half-life extension technologies, offer a promising and customizable strategy for ne
novel AXL inhibitor 4j , which was discovered through structure-based drug design, SAR-driven optimization, and pharmacokinet
target for cancer immunotherapy due to its negatively regulatory effect on the STING pathway
T cell recruitment
payload to tumor infiltrating lymphocytes
PD-1⁺ TCF1⁺) T cells, as well as CD40 high
resistance to immunotherapy and chemotherapy
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Merck SharpDohme LLC
PD-1 antibody(Merck Sharp & Dohme LLC)은 PD-1 표적 항체로, Locally Recurrent Rectal Cancer 영역에서 개발·상용화 중입니다. 작용기전: target for cancer immunotherapy due to its negatively regulatory effect on the STING pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 56.1% (ClinicalTrials.gov NCT02289209). PK: t½ 35.14 h. 차별점: novel AXL inhibitor 4j , which was discovered through structure-based drug design, SAR-driven optimization, and pharmacokinet.
PD-1
Locally Recurrent Rectal Cancer
Recruiting
to
cleavable peptide linker
humanized Fc domains and half-life extension technologies, offer a promising and customizable strategy for ne
novel AXL inhibitor 4j , which was discovered through structure-based drug design, SAR-driven optimization, and pharmacokinet
target for cancer immunotherapy due to its negatively regulatory effect on the STING pathway
T cell recruitment
payload to tumor infiltrating lymphocytes
PD-1⁺ TCF1⁺) T cells, as well as CD40 high
resistance to immunotherapy and chemotherapy
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.